BRPI0508434A - usos de 1-aminociclohexano para o tratamento de distúrbios comportamentais associados ao mal de alzheimer - Google Patents

usos de 1-aminociclohexano para o tratamento de distúrbios comportamentais associados ao mal de alzheimer

Info

Publication number
BRPI0508434A
BRPI0508434A BRPI0508434-2A BRPI0508434A BRPI0508434A BR PI0508434 A BRPI0508434 A BR PI0508434A BR PI0508434 A BRPI0508434 A BR PI0508434A BR PI0508434 A BRPI0508434 A BR PI0508434A
Authority
BR
Brazil
Prior art keywords
aminocyclohexane
disease
treatment
alzheimer
behavioral disorders
Prior art date
Application number
BRPI0508434-2A
Other languages
English (en)
Inventor
Hans-Joerg Moebius
Albrecht Stoeffler
Scott Mcdonald
Barry Reisberg
Steven A Ferris
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34919565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508434(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BRPI0508434A publication Critical patent/BRPI0508434A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USOS DE 1-AMINOCICLOHEXANO PARA O TRATAMENTO DE DISTúRBIOS COMPORTAMENTAIS ASSOCIADOS AO MAL DE ALZHEIMER A presente invenção se refere ao tratamento de distúrbios comportamentais, especialmente agitação, associados ao sistema nervoso central (CNS), especialmente mal de Alzheimer (AD), doença cérebro-vascular (VaD) ou Síndrome de Down em m mamífero, compreendendo administração, ao referido mamífero, de um 1-aminociclohexano, sozinho ou em combinação com um inibidor de acetilcolinesterase. Em uma modalidade, o 1-aminociclohexano é memantina.
BRPI0508434-2A 2004-03-03 2005-03-03 usos de 1-aminociclohexano para o tratamento de distúrbios comportamentais associados ao mal de alzheimer BRPI0508434A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55017104P 2004-03-03 2004-03-03
PCT/US2005/007244 WO2005084655A1 (en) 2004-03-03 2005-03-03 1-aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer’s disease

Publications (1)

Publication Number Publication Date
BRPI0508434A true BRPI0508434A (pt) 2007-07-24

Family

ID=34919565

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508434-2A BRPI0508434A (pt) 2004-03-03 2005-03-03 usos de 1-aminociclohexano para o tratamento de distúrbios comportamentais associados ao mal de alzheimer

Country Status (15)

Country Link
US (1) US20050203191A1 (pt)
EP (1) EP1732530A1 (pt)
JP (1) JP2007526335A (pt)
KR (2) KR20060117364A (pt)
CN (1) CN1988895A (pt)
AR (1) AR047990A1 (pt)
AU (1) AU2005219439B2 (pt)
BR (1) BRPI0508434A (pt)
CA (1) CA2556969A1 (pt)
EA (1) EA200601611A1 (pt)
IL (1) IL177787A0 (pt)
TW (1) TW200531680A (pt)
UY (1) UY28786A1 (pt)
WO (1) WO2005084655A1 (pt)
ZA (1) ZA200606834B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20060079582A1 (en) * 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006094674A1 (en) * 2005-03-07 2006-09-14 Michael Hermanussen Nmda receptor antagonists in the medical intervention of metabolic disorders
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
WO2009004440A2 (en) * 2007-06-29 2009-01-08 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
WO2009091932A2 (en) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type
IT1396556B1 (it) * 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
TWI491395B (zh) * 2009-09-30 2015-07-11 Ct Lab Inc 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP3723860A1 (en) * 2017-12-11 2020-10-21 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2021111330A1 (en) * 2019-12-02 2021-06-10 Suven Life Sciences Limited Treating behavioral and psychological symptoms in dementia patients
CN114015770B (zh) * 2021-12-30 2022-04-26 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
TW593225B (en) * 1997-06-30 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane NMDA receptor antagonists
GB9726388D0 (en) * 1997-12-12 1998-02-11 Cerebrus Ltd Chemical compounds
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
WO1999045906A1 (en) * 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
CN1486180A (zh) * 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法
AU2002354041A1 (en) * 2001-11-06 2003-05-19 John L. Haracz Antimnemonic therapy for hypermemory syndromes
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
DE60324788D1 (de) * 2002-05-31 2009-01-02 Lundbeck & Co As H Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
AU2003251993A1 (en) * 2002-07-19 2004-02-09 Inge Grundke-Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
GEP20094759B (en) * 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
RS20050851A (sr) * 2003-05-27 2008-04-04 Forest Laboratories Inc., Kombinacija antagonista nmda receptora i selektivnog inhibitora ponovnog preuzimanja serotonina za lečenje depresije i drugih poremećaja raspoloženja
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta

Also Published As

Publication number Publication date
WO2005084655A8 (en) 2007-06-21
US20050203191A1 (en) 2005-09-15
KR20080068766A (ko) 2008-07-23
TW200531680A (en) 2005-10-01
CN1988895A (zh) 2007-06-27
JP2007526335A (ja) 2007-09-13
IL177787A0 (en) 2006-12-31
AR047990A1 (es) 2006-03-15
ZA200606834B (en) 2008-12-31
AU2005219439A1 (en) 2005-09-15
WO2005084655A1 (en) 2005-09-15
AU2005219439B2 (en) 2009-04-23
KR20060117364A (ko) 2006-11-16
EA200601611A1 (ru) 2007-02-27
EP1732530A1 (en) 2006-12-20
UY28786A1 (es) 2005-04-29
CA2556969A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
BRPI0508434A (pt) usos de 1-aminociclohexano para o tratamento de distúrbios comportamentais associados ao mal de alzheimer
MX2008009947A (es) Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
WO2008011476A3 (en) Compositions and methods for modulating sirtuin activity
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
TW200716208A (en) Modified and immediate release memantine bead formulation
ATE453642T1 (de) Substituierte phenylaminopyrimidine
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
DK1703902T3 (da) Memantin til behandling af mild til moderat Alzheimer's sygdom
NO20084531L (no) Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser
BRPI0514675A (pt) ligantes de éter difenìlico terapêuticos
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
MA33218B1 (fr) Applications therapeutiques de derives de quinazolinedione
BRPI0504758A (pt) miméticos de interleucina-8 e métodos para usá-los em prevenção, tratamento, diagnóstico, e melhora dos sintomas de uma doença
BRPI0513647A (pt) derivados de ácidos 1-fenilalcanocarboxìlicos para o tratamento de doenças neurodegenerativas
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
PT1778837E (pt) Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4
ATE431855T1 (de) Menschliches autismus-suszeptibilitätsgen und verwendungen davon
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
EA200702534A1 (ru) Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.